Skip to main content

Table 1 Summary of baseline characteristics for each trial

From: Interpreting small treatment differences from quality of life data in cancer trials: an alternative measure of treatment benefit and effect size for the EORTC-QLQ-C30

  TOPICAL (N = 670) SOCCAR (N = 130) Study 10 (N = 241) Study 11 (N = 422) Study 12 (N = 724) Study 14 (N = 722)
Age (Median, range) 77 (72–82) 62 (39–75) 62 (27–81) 62 (34–81) 65 (38–86) 62 (33–84)
Gender:       
Male 409 (61 %) 79 (61 %) 136 (56 %) 296 (70 %) 412 (57 %) 465 (64 %)
Female 261 (39 %) 51 (39 %) 105 (43 %) 126 (30 %) 312 (43 %) 257 (36 %)
ECOG: 0–1 106 (16 %) 130 (100 %) 164 (68 %) 365 (86 %) 529 (73 %) 648 (90 %)
2 372 (56 %) 0 60 (25 %) 48 (11 %) 153 (21 %) 74 (10 %)
3 192 (29 %) 0 17 (7 %) 9 (21 %) 42 ( 6 %) 0
Stage: IIIa-IIIb 234 (35 %) 130 (100 %) 103 (43 %) 200 (47 %) 368a(51 %) 322 (45 %)
IV 436 (65 %) 0 138 (57 %) 222 (53 % 356a(49 %) 400 (55 %)
  1. alimited disease n = 368, extensive disease n = 356
  2. Eastern Co-operative Oncology Group (ECOG) status:
  3. 0: Fully active, able to carry on all pre-disease performance without restriction
  4. 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
  5. 2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50 % of waking hours
  6. 3 Capable of only limited self-care, confined to bed or chair more than 50 % of waking hours
  7. 4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
  8. 5 Dead